Nivolumab With Ipilimumab Have an Added Benefit in Mesotheli

A pure antibody combination is approved as first-line therapy for unresectable malignant pleural mesothelioma for the first time. Added benefit is not yet proven for patients with epithelioid histology.

Related Keywords

Germany , German , , Efficiency In Health Care Iqwi , German Institute For Quality , German Institute , Health Care , Mesothelioma , Nivolumab Ipilimumab , Drug Combination , Malignancy , Leural Tumors , Pithelioid Tumors ,